LRRK2 G2385R Leucocyte and Urine Biomarker Study (LRRK2 G2385R)
Identifying Leucocyte and Urine Biomarkers in Parkinson's Patients With LRRK2 G2385R Gene Variant
Sponsor: Max Planck Institute of Biochemistry
A observational or N/A phase clinical study on Parkinson Disease, this trial is ongoing. The trial is conducted by Max Planck Institute of Biochemistry and has accumulated 7 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Sep 2022 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Dec 2021 — Sep 2022 [monthly]
Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Jul 2020 — Nov 2020 [monthly]
Recruiting
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Max Planck Institute of Biochemistry
- Michael J. Fox Foundation for Parkinson's Research
- Nextcea, Inc
- University of Dundee
- University of Malaya
For direct contact, visit the study record on ClinicalTrials.gov .